Company

Alector, Inc.

Headquarters: South San Francisco, CA, United States

Employees: 208

CEO: Dr. Arnon Rosenthal

NASDAQ: ALEC +0.96%

Market Cap

$630.2 Million

USD as of Jan. 1, 2024

Market Cap History

Alector, Inc. market capitalization over time

Evolution of Alector, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Alector, Inc.

Detailed Description

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Alector, Inc. has the following listings and related stock indices.


Stock: NASDAQ: ALEC wb_incandescent

Stock: FSX: 0Z2 wb_incandescent

Details

Headquarters:

131 Oyster Point Boulevard

Suite 600

South San Francisco, CA 94080

United States

Phone: 415 231 5660